Muhammed BEKÇİBAŞI, Özcan DEVECİ, Recep TEKİN, Saim DAYAN, Salih HOŞOĞLU

Meropenem tedavisi altında gelişen intrahepatik kolestaz olgusu

İntrahepatik kolestaz safranın bağırsağa kısmen ya da tamamen ulaşamamasıyla ortaya çıkan klinik tablo olup ilaçlar başta olmak üzere birçok neden etyolojide yer alabilmektedir. Meropenem uzun yıllardır klinik kullanımda olan geniş spektrumlu karbapenem grubu bir antibiyotik olup, yan etki meta-analizlerinde % 1-4 oranında karaciğer enzim yüksekliğine neden olduğu gözlenmiştir. Bu yazıda, meropenem tedavisiyle ortaya çıkan intrahepatik kolestaz olgusu sunulmuştur.

A case of intrahepatic cholestasis developed under treatment with meropenem

Intrahepatic cholestasis is defined as a clinical entity in which bile can not flow to the intestine, partially or completely. Meropenem is a broad-spectrum carbapenem group antibiotic which is in clinical use for many years. In a meta-analysis study which was investigated adverse effects of meropenem, elevation of liver enzymes was observed in the rate of 1-4 %. Herein, we presented a case of meropenem induced intrahepatic cholestasis.

PDF

___

1. Harrison MP, Moss SR, Featherstone A, Fowkes AG, Sanders AM, Case DE. The disposition and metabolism of meropenem in laboratory animals and man, J Antimicrob Chemother 1989;24(Suppl A):265-77. http://dx.doi.org/10.1093/jac/24.suppl_A.265 PMid:2808212
2. Lee WM. Drug-induced hepatotoxicity, N Engl J Med 2003;349(5):474-85. http://dx.doi.org/10.1056/NEJMra021844 PMid:12890847
3. Naranjo CA, Busto U, Sellers EM. A method for estimating the probability of adverse drug reactions, Clin Pharmacol Ther 1981;30(2):239-45. http://dx.doi.org/10.1038/clpt.1981.154 PMid:7249508
4. Norrby SR, Gildon KM. Safety profile of meropenem: a review of nearly 5,000 patients treated with meropenem, Scand J Infect Dis 1999;31(1):3-10. http://dx.doi.org/10.1080/00365549950161808 PMid:10381210
5. İdilman R. İntrahepatik kolestaz nedenleri ve tanı yöntemleri, Türkiye Klinikleri J Int Med Sci 2006;2(34):22-6.
6. Schumaker AL, Okulicz JF. Meropenem-induced vanishing bile duct syndrome, Pharmacotherapy 2010;30(9):953. http://dx.doi.org/10.1592/phco.30.9.953 PMid:20812433
7. Thyrum PT, Yeh C, Birmingham B, Lasseter K. Pharmacokinetics of meropenem in patients with liver disease, Clin Infect Dis 1997;24(Suppl 2):184-90. http://dx.doi.org/10.1093/clinids/24.Supple-ment_2.S184 PMid:9126692